TSE:GUD - Knight Therapeutics Inc. (GUD.TO) Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$7.56
  • Forecasted Upside: 40.83 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
C$5.37
▼ -0.14 (-2.54%)
1 month | 3 months | 12 months
Get New Knight Therapeutics Inc. (GUD.TO) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GUD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GUD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
C$7.56
▲ +40.83% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Knight Therapeutics Inc. (GUD.TO) in the last 3 months. The average price target is C$7.56, with a high forecast of C$8.00 and a low forecast of C$6.75. The average price target represents a 40.83% upside from the last price of C$5.37.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Knight Therapeutics Inc. (GUD.TO). This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/10/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/8/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/7/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
11/16/2020National Bank FinancialLower Price TargetOutperformC$8.25 ➝ C$6.75
i
11/16/2020Raymond JamesLower Price TargetOutperformC$10.25 ➝ C$8.00
i
11/16/2020Royal Bank of CanadaLower Price TargetOutperformC$8.00 ➝ C$7.50
i
9/23/2020Raymond JamesSet Price TargetOutperformC$10.25
i
8/27/2020Royal Bank of CanadaLower Price TargetOutperformC$9.50 ➝ C$8.00
i
8/26/2020Raymond JamesSet Price TargetOutperformC$10.25
i
8/17/2020Raymond JamesSet Price TargetOutperformC$10.25
i
6/29/2020Bloom BurtonDowngradeBuy ➝ Accumulate
i
Rating by D. Martin at Bloom Burton
6/29/2020National Bank FinancialLower Price TargetOutperformC$8.75 ➝ C$8.25
i
6/29/2020Raymond JamesSet Price TargetOutperformC$10.25
i
5/4/2020National Bank FinancialLower Price TargetOutperformC$9.00 ➝ C$8.75
i
4/20/2020Raymond JamesSet Price TargetOutperformC$10.25
i
4/1/2020Raymond JamesSet Price TargetOutperformC$10.25
i
4/1/2020Canaccord GenuityLower Price TargetC$9.75 ➝ C$8.00
i
3/31/2020National Bank FinancialLower Price TargetOutperformC$9.25 ➝ C$9.00
i
3/5/2020National Bank FinancialLower Price TargetC$10.00 ➝ C$9.25
i
1/9/2020Raymond JamesSet Price TargetOutperformC$10.25
i
11/22/2019Raymond JamesSet Price TargetOutperformC$10.25
i
11/13/2019Raymond JamesReiterated RatingOutperformC$10.25
i
10/22/2019Bloom BurtonUpgradeAccumulate ➝ Buy
i
Rating by D. Martin at Bloom Burton
10/22/2019Raymond JamesSet Price TargetOutperformC$10.25
i
10/22/2019National Bank FinancialBoost Price TargetOutperformC$9.50 ➝ C$10.00
i
10/15/2019Canaccord GenuityReiterated RatingBuyC$8.50
i
10/9/2019Raymond JamesReiterated RatingOutperformC$10.25
i
8/9/2019Raymond JamesSet Price TargetOutperformC$10.25
i
7/18/2019Raymond JamesReiterated RatingOutperformC$10.25
i
5/8/2019Raymond JamesReiterated RatingOutperformC$10.25
i
4/5/2019Raymond JamesReiterated RatingOutperformC$10.25
i
3/15/2019Raymond JamesSet Price TargetOutperformC$10.25
i
3/1/2019Raymond JamesReiterated RatingOutperformC$10.25
i
1/16/2019Raymond JamesReiterated RatingOutperformC$10.25
i
11/9/2018Bloom BurtonReiterated RatingAccumulate
i
Rating by D. Martin at Bloom Burton
8/10/2018TD SecuritiesBoost Price TargetC$9.50 ➝ C$10.00
i
7/12/2018Raymond JamesSet Price TargetOutperformC$10.25
i
5/11/2018CormarkReiterated RatingBuyC$10.50
i
4/26/2018Beacon SecuritiesReiterated RatingBuy
i
Rating by D. Kideckel at Beacon Securities
4/23/2018Royal Bank of CanadaReiterated RatingOutperformC$9.50
i
11/13/2017National Bank FinancialLower Price TargetOutperformC$10.75 ➝ C$10.50
i
8/11/2017National Bank FinancialLower Price TargetC$11.75 ➝ C$10.75
i
Rating by E. Leno at National Bank Financial
5/12/2017ScotiabankLower Price TargetOutperformC$11.00 ➝ C$10.50
i
3/20/2017TD SecuritiesReiterated RatingBuyC$12.50
i
3/17/2017ScotiabankBoost Price TargetOutperformC$10.50 ➝ C$11.00
i
3/16/2017National Bank FinancialReiterated RatingOutperform Market Weight
i
Rating by E. Leno at National Bank Financial
3/15/2017National Bank FinancialBoost Price TargetC$11.00 ➝ C$11.75
i
3/14/2017TD SecuritiesReiterated RatingBuyC$12.50
i
2/9/2017TD SecuritiesReiterated RatingBuyC$12.50
i
1/13/2017CIBCLower Price TargetC$13.00 ➝ C$9.80
i
1/9/2017TD SecuritiesBoost Price TargetBuyC$11.00 ➝ C$12.50
i
1/4/2017MackieDowngradeBuy ➝ HoldC$12.00 ➝ C$10.75
i
12/23/2016ScotiabankBoost Price TargetOutperformC$10.00 ➝ C$10.50
i
11/11/2016TD SecuritiesBoost Price TargetBuyC$10.00 ➝ C$11.00
i
11/11/2016ScotiabankLower Price TargetOutperformC$10.00 ➝ C$9.50
i
11/11/2016CIBCBoost Price TargetC$9.50 ➝ C$9.80
i
11/10/2016Bloom BurtonReiterated RatingAccumulate
i
Rating by D. Martin at Bloom Burton
7/18/2016ScotiabankReiterated RatingOutperformC$9.50
i
6/7/2016TD SecuritiesLower Price TargetBuyC$10.00 ➝ C$9.00
i
5/31/2016CIBCReiterated RatingOutperformC$9.50
i
5/12/2016ScotiabankBoost Price TargetOutperformC$9.00 ➝ C$9.50
i
4/15/2016ScotiabankReiterated RatingOutperformC$9.00
i
Rating by A. Ridgeway at Scotiabank
3/10/2016Paradigm CapitalSet Price TargetBuyC$9.00
i
3/2/2016Dundee SecuritiesReiterated RatingNeutral
i
Rating by A. Salz at Dundee Securities
12/15/2015TD SecuritiesReiterated RatingBuyC$9.00
i
(Data available from 12/1/2015 forward)
Knight Therapeutics Inc. (GUD.TO) logo
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; NERLYNX for the treatment of HER2-positive breast cancer; and Trelstar for prostate cancer. It also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; NeurAxon family for acute migraine, pain and neurological disorders; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to tre Ibsrela at tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; Burinex for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease; Impavido, an oral drug treatment based on miltefosine for the visceral, cutaneous, and mucocutaneous leishmaniasis; and Imvexxy for moderate-to-severe dyspareunia and Bijuva for moderate-to-severe vasomotor symptoms due to menopause. It develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. It develops TULSA-PRO, a medical device for prostate ablation. It finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: C$5.37
C$5.37
C$5.53

50 Day Range

MA: C$5.52
C$5.32
C$5.76

52 Week Range

Now: C$5.37
C$4.73
C$8.12

Volume

308,497 shs

Average Volume

313,153 shs

Market Capitalization

C$703.14 million

P/E Ratio

26.98

Dividend Yield

N/A

Beta

N/A